A significant outbreak of a rare strain of Ebola, known as Bundibugyo, is currently affecting central Africa, particularly in the Democratic Republic of Congo (DRC) and Uganda. The World Health Organization (WHO) has classified the outbreak's public health risk as 'very high', with over 900 suspected cases and 119 deaths reported, including the tragic fatalities of three Red Cross volunteers. Unlike the more common Zaire variant, there is currently no vaccine available for the Bundibugyo strain, which raises concerns about the outbreak’s potential to spread further. The variant, which was first recorded in 2007, spreads through direct contact with bodily fluids and can remain asymptomatic for up to 21 days, complicating containment efforts. The UK government has committed up to £20 million to help manage the crisis, while experts stress the importance of global vigilance and funding to combat infectious diseases. Researchers at Oxford University are working on a vaccine, but it may take several months before it can be tested on humans, leaving affected populations vulnerable in the interim.